Allogene Therapeutics Funding & Investors
South San Francisco, CA
Allogene Therapeutics, Inc. operates as a biotechnology company. The Company develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in the State of California.
allogene.comTotal Amount Raised: $1,011,770,368
Allogene Therapeutics Funding Rounds
Post Ipo Equity
$110,000,000
Post Ipo Equity
$250,000,000
Convertible Note
$120,000,000
Convertible Note Investors
Perceptive AdvisorsDeerfield Capital ManagementFidelity InvestmentsJennison AssociatesFranklin ResourcesT. Rowe PriceSurveyor CapitalAvoro Capital Advisors (formerly venBio Select Advisor)RamiusConvertible Note
$120,000,000
Series A
$411,770,409
Series A Investors
TPGVida VenturesPfizerTwo RiverBellco CapitalGilead SciencesIPO
Unknown
Funding info provided by Diffbot.